SGN-CD19B

N/A

Report date: 2024/02/05 14:09:13

Base Information

Drug NameSGN-CD19B

Drug Alias NameSGN-CD19B

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SGD-1882 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionDNA cross linking agentsB-lymphocyte antigen CD19 inhibitors

TargetsB-lymphocyte antigen CD19DNA

Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSeagen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSeagen Inc

Active IndicationsN/A

Inactive IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin

Other Information

ATC CodeN/A